Clinical Trial Update: Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating rectal indomethacin to prevent post-ERCP pancreatitis in high-risk patients was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-ercp Pancreatitis

Drugs mentioned

• INDOMETHACIN (INDOMETHACIN)

Snippet

Sponsor: University of Michigan | Conditions: Post-ERCP Pancreatitis | Phase 4 | Status: TERMINATED | Results posted: 2013-02-12